Morgan Stanley Maintains Merck & Co Buy Rating at $179

Morgan Stanley analyst Terence Flynn has maintained his buy rating for Merck & Co (MRK.US), leaving its target price at $179. According to TipRanks data, Flynn's success rate over the past year is 59.2%, with an average return of 9.7%. This means that nearly six out of ten times, Flynn's recommendations have generated a positive return for investors.

Flynn's maintained rating and target price may come as good news for existing Merck & Co shareholders, who can now set their sights on the $179 mark. However, it is essential to remember that past performance does not guarantee future success. TipRanks provides analysis data from financial analysts, offering insights into their track records.